ANEBOTCPharmaceutical PreparationsFiscal year ends June 30
Anebulo Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Dec 31, 2025Last filing: 10-Q on Feb 12, 2026
$0.00+0.00 (+75.00%)
Close on Oct 19, 2026
- Market cap
- $28.76K
- P/E (TTM)
- –
- Dividend yield
- –
Debt
Borrowings on the balance sheet, Dec 31, 2025
Anebulo Pharmaceuticals reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
Bond issues
Individual notes and bonds outstanding
Bond-level data is not connected yet
Coupon, maturity and amount of each note will come from the debt footnote in Anebulo Pharmaceuticals's annual report. Trading prices and yields need FINRA TRACE data.